Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Change in Receivables (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Change in Receivables over the past 16 years, most recently at $1.7 million for Q2 2025.

  • Quarterly results put Change in Receivables at $1.7 million for Q2 2025, up 200.72% from a year ago — trailing twelve months through May 2025 was $2.3 million (down 30.68% YoY), and the annual figure for FY2025 was $2.3 million, down 30.68%.
  • Change in Receivables for Q2 2025 was $1.7 million at Lifecore Biomedical, Inc. \De\, up from $1.3 million in the prior quarter.
  • Over the last five years, Change in Receivables for LFCR hit a ceiling of $12.1 million in Q1 2022 and a floor of -$19.9 million in Q2 2023.
  • Median Change in Receivables over the past 5 years was $570000.0 (2021), compared with a mean of -$1.2 million.
  • Peak annual rise in Change in Receivables hit 290.17% in 2022, while the deepest fall reached 1420.18% in 2022.
  • Lifecore Biomedical, Inc. \De\'s Change in Receivables stood at $3.5 million in 2021, then soared by 109.43% to $7.2 million in 2022, then crashed by 50.37% to $3.6 million in 2023, then soared by 50.08% to $5.4 million in 2024, then plummeted by 69.21% to $1.7 million in 2025.
  • The last three reported values for Change in Receivables were $1.7 million (Q2 2025), $1.3 million (Q1 2025), and $5.4 million (Q4 2024) per Business Quant data.